Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 37 of 157 for:    eribulin

Combination of Carboplatin, Eribulin Mesylate, and E7449 in BRCA-Related Cancers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02396433
Recruitment Status : Withdrawn (lack of funding.)
First Posted : March 24, 2015
Last Update Posted : August 25, 2015
Sponsor:
Information provided by (Responsible Party):
Virginia G. Kaklamani, The University of Texas Health Science Center at San Antonio

Brief Summary:
Non-randomized, open-label, multi-center, phase I/II, dose-escalation study of the combination of carboplatin, eribulin, and E7449.

Condition or disease Intervention/treatment Phase
Cancer of the Breast Drug: Carboplatin Drug: Eribulin Drug: E7449 Phase 1 Phase 2

Detailed Description:
This is a phase I/II clinical trial of the combination of carboplatin, eribulin, and E7449. A cycle will be defined as 21 days. Carboplatin will be given on day 1 of each cycle. Eribulin will be given on days 1 and 8 of each cycle. E7449 will be given daily (days 1-21) during each cycle. Patients will continue to receive treatment until progression of disease or discontinuation due to unacceptable side effects.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I/II Clinical Trial of the Combination of Carboplatin, Eribulin Mesylate, and E7449 in Patients With BRCA-Related Cancers
Study Start Date : April 2015
Actual Primary Completion Date : April 2015
Actual Study Completion Date : April 2015

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Carboplatin, eribulin, and E7449
This is a phase I/II clinical trial of the combination of carboplatin, eribulin, and E7449.
Drug: Carboplatin
Carboplatin will be given on day 1 of each cycle.
Other Name: Paraplatin

Drug: Eribulin
Eribulin will be given on days 1 and 8 of each cycle.
Other Name: Halaven

Drug: E7449
E7449 will be given daily (days 1-21) during each cycle. Patients will continue to receive treatment until progression of disease or discontinuation due to unacceptable side effects.
Other Name: PARP inhibitor




Primary Outcome Measures :
  1. Safety of E7449 will be measured by the number, frequency and severity of adverse events. [ Time Frame: Baseline to 24 months ]
    Patients will be evaluated by MD at clinic visits during Cycle 1, on Day 1 of all 21-day cycles, and will have additional evaluations if clinically indicated.

  2. MTD (maximum tolerated dose) of E7449 will be measured by the number, frequency and severity of adverse events. [ Time Frame: Baseline to 21 days ]
    Maximum tolerated dose (MTD) defined as highest dose studied in which the incidence of non-hematologic DLT (dose limiting toxicity) is defined as any Grade ≥ 3 toxicity, and a hematologic DLT is defined as any Grade ≥ 4 toxicity, both by CTCAE v 4.03 criteria.


Secondary Outcome Measures :
  1. Overall response rate will be measured by the evaluation of target and non-target lesions for changes in tumor measurements. [ Time Frame: Baseline to first occurrence of disease progression or death. (up to 6 weeks) ]
    The overall response rate (ORR) will be defined as response after scans (CT or MRI) assessed after two cycles of therapy (1 cycle = 3 weeks).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Phase I only

  • Patients must have stage IV breast or ovarian cancer or another BRCA mutation-related cancer.
  • Patients may have either measurable or evaluable disease per RECIST 1.1 criteria.

NOTE: Measurable lesions are defined as those that can be accurately measured in at least one dimension (longest diameter to be recorded) as >20 mm with conventional techniques or as >10 mm with spiral CT scan.

  • Patients must be refractory to / intolerant of established therapy known to provide clinical benefit for their condition.

Both Phase I & II

  • Patients must have archival biopsy specimens (preferably from metastatic disease) available for research tests. If a suitable biopsy specimen is not available, patients will be asked to undergo a research biopsy to procure tissue.
  • Patients must be ≥ 18 years.
  • Females of childbearing potential must not have had unprotected sexual intercourse within 30 days prior to study entry and must agree to use a highly effective method of contraception. Females who are using hormonal contraceptives must have been on a stable dose of the same hormonal contraceptive product for at least 4 weeks prior to dosing and must continue to use the same contraceptive during the study and for 30 days after study drug discontinuation
  • Patients must have an ECOG performance status 0-1.
  • Patients may have had a prior diagnosis of cancer if it has been > 5 years since their last treatment for that cancer.
  • Patients must have normal organ and marrow function as defined below:

Leukocytes ≥ 3,000/μL Absolute neutrophil count ≥ 1,500/μL Platelets ≥ 100,000/μL Creatinine within normal limits or creatinine clearance ≥30

  • Patients must be able to swallow and retain oral medication.
  • Patients who were receiving prior systemic therapy: Prior treatment related side effects must have resolved to < Grade 2 severity (except alopecia and infertility).
  • All patients must have given signed, informed consent prior to registration on study.

Phase II Only

  • Patients must have stage IV breast or ovarian cancer
  • Patients must have BRCA1/2 deleterious mutations, PTEN deficiency, or cancer with a high HRD score as assessed by Myriad's assay
  • Patients must have measurable disease per RECIST 1.1 criteria (see above for definition).
  • Patients may not have received more than 3 chemotherapeutic regimens for metastatic disease.
  • Patients who may not have received treatment with prior carboplatin, eribulin or a PARP inhibitor.

Exclusion Criteria:

  • Women who are pregnant or lactating are not eligible
  • Patients who are undergoing concomitant radiotherapy are not eligible.
  • Patients who are receiving any other investigational agents or concurrent anticancer therapy are not eligible.

NOTE: Previous systemic treatment is allowed with a 14 day (Phase I) or 21 day (Phase II) washout period prior to registration.

  • Patients who are taking any herbal (alternative) medicines are not eligible. Patients must be off any such medications by the time of registration.
  • Patients with known brain metastases are not eligible for participation unless the following are met:

Brain metastases are treated (either with surgical excision, stereotactic radiosurgery or radiotherapy and have been stable for at least 4 weeks (MRI documented) Patient is asymptomatic and has discontinued corticosteroids if taken for that purpose

Patients with any of the following conditions or complications are NOT eligible for participation:

GI tract disease resulting in an inability to take oral medication Malabsorption syndrome Require IV alimentation History of prior surgical procedures affecting absorption Uncontrolled inflammatory GI disease (e.g., Crohn's, ulcerative colitis). Hypersensitivity of any of the components of E7449, carboplatin, eribulin History of significant neurological (no neuropathy > Grade 2) or psychiatric disorders.

Significant non-neoplastic liver disease (e.g., cirrhosis, active chronic hepatitis).

Significant non-neoplastic renal disease. Immunocompromised subjects, including subjects known to be infected with human immunodeficiency virus (HIV).

Uncontrolled endocrine diseases (e.g., diabetes mellitus, hypothyroidism or hyperthyroidism, adrenal disorder) i.e., requiring relevant changes in medication within the last month or hospital admission within the last three months Active infection requiring systemic therapy. Significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) Class II, uncontrolled arterial hypertension, unstable angina, myocardial infarction or stroke within 6 months of the first dose of study drug; or cardiac arrhythmia requiring medical treatment.

Prolongation of QTc interval to > 480 msec when electrolytes balance is normal. Major surgery within 4 weeks prior to the first dose of study drug


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02396433


Sponsors and Collaborators
The University of Texas Health Science Center at San Antonio
Investigators
Layout table for investigator information
Principal Investigator: Virginia Kaklamani UTHSCSA@CTRC

Layout table for additonal information
Responsible Party: Virginia G. Kaklamani, Professor of Medicine Hematology/ Oncology, The University of Texas Health Science Center at San Antonio
ClinicalTrials.gov Identifier: NCT02396433     History of Changes
Other Study ID Numbers: CTMS# 14-2024
First Posted: March 24, 2015    Key Record Dates
Last Update Posted: August 25, 2015
Last Verified: August 2015

Keywords provided by Virginia G. Kaklamani, The University of Texas Health Science Center at San Antonio:
Halaven
BRCA
E7449

Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Carboplatin
Antineoplastic Agents